Now that Taiwan's government has set its sights on spurring the rise of drug makers capable of developing new pharmaceuticals as a means of achieving rapid growth in the biotech industry, how are the country's traditional pharmaceutical firms to adapt?
如今，政府既已鎖定「新藥研發」作為鼓動生技產業起飛的發動機，傳統製藥產業又該如何因應、調適？